ClinicaliQ Trial Snapshot
- A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy — Recruiting • Phase III • NCT06129864.
- Trial testing a new drug (volrustomig) versus monitoring in head and neck cancer patients after chemoradiotherapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT). Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma Interventions: volrustomig Lead Sponsor: AstraZeneca Planned Enrollment: 1145 participants